Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change ...

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change ...

First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3 and T4 less than the upper limit of normal) at the end…

Immunovants Batoclimab Shows Promising Six-Month Remission Data, Potentially Transforming Management of Uncontrolled...

In a significant development for the management of uncontrolled Graves' disease (GD), Immunovant, Inc. has released pivotal data concerning its investigational therapy, batoclimab. The findings, which will be formally presented at the upcoming Annual Meeting of the American Thyroid Association (ATA) on September 11, 2025, indicate that patients treated with batoclimab experienced a six-month, treatment-free remission following a 24-week course o…

80% Success Rate: Roivant's Groundbreaking Graves' Disease Treatment Shows 6-Month Remission Potential

Clinical trial shows 17/21 patients maintained normal thyroid function 6 months post-treatment, with 50% achieving drug-free remission. Two registrational trials now enrolling for IMVT-1402.